© 2004 by Oxford University Press
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
© 2004 Oxford University Press
NEWS |
Three Molecularly Targeted Drugs Tested in Kidney Cancer Clinical Trials
| The first 10% of the full text of this article appears below. |
Kidney cancer is difficult to treat; for most patients, only surgery offers the prospect of curing the disease, and chemotherapy and radiation offer only palliative benefit. But early results from three phase I/II studies of three molecularly targeted drugs presented at this year's annual meeting of the American Society of Clinical Oncology (ASCO) suggest that targeting the underlying biology of these tumors is worthy of further study.
Clear-cell renal cancer is the most common form of kidney cancer, and the
tumors in 90% of these patients have lost the Von Hippel-Lindau (VHL) tumor
suppressor gene. Loss of this activity stimulates expression of vascular
endothelial growth factor (VEGF) and platelet-derived growth factor
(PDGF)both of which are
Related Stat Bite
![]()
CiteULike
Connotea
Del.icio.us What's this?
J Natl Cancer Inst 2004 96: 1271.